Oscar Health, Inc. (NYSE:OSCR) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Analyst consensus: Hold — 11 analysts cover Oscar Health (2 sell, 7 hold, 2 buy) with an average 12‑month price target of about $16.78.
• Insider buy: CEO Mark T. Bertolini purchased 1,000,000 shares at $11.92 on April 6, increasing his stake by 10.87%; insiders now own 24.39% of the company.
• Earnings miss: Oscar reported Q earnings of ($1.24) vs. ($0.92) expected and revenue of $2.81B vs. $3.12B expected, leaving negative profitability metrics despite 17.3% year‑over‑year revenue growth.

Oscar Health, Inc. (NYSE:OSCR - Get Free Report) has earned a consensus rating of "Hold" from the eleven ratings firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $16.7778.

Several equities research analysts have recently weighed in on the company. Wall Street Zen raised Oscar Health from a "sell" rating to a "hold" rating in a research report on Saturday, February 14th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Oscar Health in a research report on Tuesday, April 21st. UBS Group reaffirmed a "neutral" rating and issued a $15.00 target price on shares of Oscar Health in a research report on Wednesday, February 11th. Barclays set a $18.00 target price on Oscar Health and gave the stock an "equal weight" rating in a research report on Monday, January 5th. Finally, Jefferies Financial Group raised Oscar Health from an "underperform" rating to a "hold" rating and upped their target price for the stock from $10.00 to $16.00 in a research report on Monday, April 20th.

Oscar Health Price Performance

Shares of NYSE OSCR opened at $18.45 on Friday. Oscar Health has a 1-year low of $10.69 and a 1-year high of $23.80. The business has a 50-day moving average of $14.02 and a 200-day moving average of $15.38. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.96 and a quick ratio of 0.96. The company has a market capitalization of $5.49 billion, a price-to-earnings ratio of -10.60 and a beta of 2.34.

Oscar Health (NYSE:OSCR - Get Free Report) last issued its earnings results on Tuesday, February 10th. The company reported ($1.24) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.32). Oscar Health had a negative return on equity of 39.35% and a negative net margin of 3.79%.The company had revenue of $2.81 billion during the quarter, compared to analysts' expectations of $3.12 billion. During the same period in the previous year, the company earned ($0.62) EPS. Oscar Health's quarterly revenue was up 17.3% on a year-over-year basis. On average, equities analysts anticipate that Oscar Health will post 0.2 EPS for the current fiscal year.

Insider Buying and Selling

In other Oscar Health news, CEO Mark T. Bertolini purchased 1,000,000 shares of Oscar Health stock in a transaction that occurred on Monday, April 6th. The stock was purchased at an average price of $11.92 per share, with a total value of $11,920,000.00. Following the completion of the acquisition, the chief executive officer owned 10,196,876 shares of the company's stock, valued at approximately $121,546,761.92. This trade represents a 10.87% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 24.39% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of OSCR. Thrive Capital Management LLC boosted its holdings in Oscar Health by 33.4% in the fourth quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company's stock valued at $85,258,000 after purchasing an additional 1,588,395 shares during the last quarter. Baird Financial Group Inc. purchased a new position in Oscar Health in the first quarter valued at about $159,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Oscar Health by 4.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 215,650 shares of the company's stock valued at $2,827,000 after purchasing an additional 8,879 shares during the last quarter. Jones Financial Companies Lllp boosted its holdings in Oscar Health by 7,473.3% in the first quarter. Jones Financial Companies Lllp now owns 2,272 shares of the company's stock valued at $30,000 after purchasing an additional 2,242 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Oscar Health by 39.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 470,590 shares of the company's stock valued at $6,169,000 after purchasing an additional 132,149 shares during the last quarter. Hedge funds and other institutional investors own 75.70% of the company's stock.

Oscar Health Company Profile

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company's primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.